Tevogen Bio regains Nasdaq minimum bid price compliance after reverse split

Tevogen Bio Holdings Inc.

Received Nasdaq notice on March 20, 2026 confirming compliance with Listing Rule 5450(a)(1).
Compliance achieved via 1-for-50 reverse stock split of common stock effective March 6, 2026.
Nasdaq matter now closed; no further delisting risk from this requirement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.